Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELMO domain-containing protein 2 (ELMOD2)
- Target
- ELMOD2
- Molecular classification
- Other (specifically: GTPase-activating protein for ARF family GTPases)
01
Overview
ELMO domain-containing protein 2 (ELMOD2) is a GTPase-activating protein (GAP) with broad specificity for ARF family GTPases, particularly ARL2 and ARF6[1][2]. It is involved in several biological processes, including regulation of mitochondrial fusion through interaction with ARL2, stabilization and nucleation of microtubules (key for cell structure and division), and facilitation of cytokinesis via ARF6-dependent pathways[1][2]. ELMOD2 is also crucial for balancing ciliary homeostasis and maintaining the organization of centrosomal rootlet structures, acting in pathways alongside Rootletin and ARL2 to suppress inappropriate cilia formation and preserve centrosome cohesion[2]. ELMOD2 is primarily intracellular, localizing to mitochondria, endoplasmic reticulum, lipid droplets, basal bodies, centrosomes, and ciliary rootlets[1][2]. While loss of ELMOD2 function disrupts cellular processes, causes mitochondrial fragmentation, defective cytokinesis, increased and abnormal ciliation, and rootlet disorganization, there are no current direct disease associations or therapies targeting ELMOD2[1][2].
- Other names
- ELMO domain-containing protein 2ELMOD2MGC100849830169G11RikELMO/CED-12 domain containing 2
02
Mechanism of action
Not applicable (no drugs identified)
03
Biological functions
GTPase activating protein (GAP) activity, especially toward ARF family GTPases (notably ARL2 and ARF6)Regulation of mitochondrial fusion and mitochondrial functionRegulation of microtubule nucleation and stabilityRegulation of cytokinesis (cell division abscission)Suppression of spurious ciliation and regulation of ciliogenesisMaintenance of centrosome cohesion and rootlet organization
04
Disease associations
Other (ELMOD2 loss is associated experimentally with cellular defects relevant to processes such as cytokinesis and ciliary dysfunction, but there are no strong links to major human diseases like cancer, neurodegeneration, or cardiovascular disease reported in current literature)
05
Safety considerations
No direct therapeutic targeting or associated safety concerns reported, as ELMOD2 is not considered a known drug target
06
Interacting drugs
None identified in the literature; no approved or experimental drugs directly targeting ELMOD2 are known
07
Biomarkers
None specifically identified for patient selection or efficacy monitoring
Beyond the preview
Go deeper on ELMO domain-containing protein 2 (ELMOD2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELMO domain-containing protein 2 (ELMOD2).